Easywell Biomedicals, Inc. (1799.TWO)
TWD 62.7
(2.96%)
TWD 62.7
(2.96%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -151.44 Million | -53.5 Million | -128.3 Million | -157.87 Million | - |
| Net Income | -169.9 Million | -168.27 Million | -169.66 Million | -182.81 Million | - |
| Depreciation & Amortization | 65.15 Million | 66.54 Million | 70.87 Million | 80.93 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 16.96 Million | - | - | - | -964 Thousand |
| Change in working capital | -63.6 Million | 48.41 Million | -11.32 Million | -52.9 Million | - |
| Other non-cash items | 15.99 Million | 15.06 Million | -2.21 Million | 15.67 Million | - |
| Investing Cash Flow | 87.46 Million | 72.66 Million | -182.54 Million | -50.35 Million | - |
| Investments in PPE | -18.54 Million | -7.49 Million | -7.71 Million | -17.15 Million | - |
| Acquisitions | 400 Thousand | - | - | - | -14.18 Million |
| Investment purchases | - | -10.58 Million | -185.54 Million | -34.7 Million | - |
| Sales/Maturities of investments | 106.37 Million | 90.73 Million | 10.47 Million | - | - |
| Other Investing Activities | -367 Thousand | 8000.00 | - | 3000.00 | 176 Thousand |
| Financing Cash Flow | 177.84 Million | -10.55 Million | 320.31 Million | 107.3 Million | - |
| Debt repayment | -43.93 Million | - | - | -84.06 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 15 Million | - | 329.76 Million | 200.48 Million | - |
| Other Financing Activities | 134.38 Million | - | - | - | - |
| Accounts receivables | -44.83 Million | - | - | - | - |
| Accounts payables | 7.17 Million | - | - | - | - |
| Inventory | -15.58 Million | -3.91 Million | 9.95 Million | -24.63 Million | - |
| Other working capital | -3.18 Million | - | - | - | - |
| Cash at beginning of period | 159.02 Million | 153.02 Million | 144.88 Million | 237.26 Million | - |
| Cash at end of period | 262.9 Million | 159.02 Million | 153.02 Million | 144.88 Million | - |
| Capital Expenditure | -18.54 Million | -7.49 Million | -7.71 Million | -17.15 Million | - |
| Effect of forex changes on cash | -9.97 Million | -2.61 Million | -1.32 Million | 8.55 Million | - |
| Net cash flow / Change in cash | 103.88 Million | 5.99 Million | 8.13 Million | -92.37 Million | - |
| Free Cash Flow | -169.99 Million | -60.99 Million | -136.01 Million | -175.02 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -20.68 Million | -55.65 Million | -169.9 Million | -54.38 Million | -36.24 Million | -26.63 Million |
| Depreciation & Amortization | 19.66 Million | 17.27 Million | 65.15 Million | 16.82 Million | 16.55 Million | 16.05 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.87 Million | 5.96 Million | 16.96 Million | - | - | - |
| Change in working capital | -72.03 Million | 9.16 Million | -63.6 Million | -46.7 Million | -22.31 Million | -10.67 Million |
| Other non-cash items | 3.37 Million | 4.12 Million | 15.99 Million | 4.1 Million | 4.36 Million | 4.17 Million |
| Investing Cash Flow | -8.58 Million | -83.07 Million | 87.46 Million | -604 Thousand | 42.3 Million | 18.37 Million |
| Investments in PPE | -7.62 Million | -3.05 Million | -18.54 Million | -63 Thousand | -7.59 Million | -9.04 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -974 Thousand | -133.78 Million | - | - | 764 Thousand | -4000.00 |
| Sales/Maturities of investments | -9000.00 | 53.75 Million | 106.37 Million | -537 Thousand | 49.3 Million | 27.6 Million |
| Other Investing Activities | -1.08 Million | - | -367 Thousand | -4000.00 | -177 Thousand | - |
| Financing Cash Flow | -19.18 Million | 183.73 Million | 177.84 Million | 97.01 Million | 40.25 Million | 42.96 Million |
| Debt repayment | -7.65 Million | -7.65 Million | -43.93 Million | -4.15 Million | -257 Thousand | -48.34 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 171.6 Million | 15 Million | - | - | - |
| Other Financing Activities | -7.41 Million | 8.07 Million | 134.38 Million | 90.07 Million | 43.91 Million | - |
| Accounts receivables | 2.23 Million | - | - | - | - | - |
| Accounts payables | 26.34 Million | - | - | - | - | - |
| Inventory | -86.38 Million | -16.61 Million | -15.58 Million | 55 Thousand | -13.24 Million | 7.95 Million |
| Other working capital | -2.37 Million | - | - | - | - | - |
| Cash at beginning of period | 344.14 Million | 262.9 Million | 159.02 Million | 237.87 Million | 200.15 Million | 163.79 Million |
| Cash at end of period | 247.05 Million | 344.14 Million | 262.9 Million | 262.9 Million | 237.87 Million | 200.15 Million |
| Capital Expenditure | -7.62 Million | -3.05 Million | -18.54 Million | -63 Thousand | -7.59 Million | -9.04 Million |
| Effect of forex changes on cash | 1.01 Million | 3.93 Million | -9.97 Million | -4.94 Million | -1.92 Million | -3.77 Million |
| Net cash flow / Change in cash | -97.09 Million | 81.24 Million | 103.88 Million | 25.02 Million | 37.72 Million | 36.35 Million |
| Free Cash Flow | -77.96 Million | -26.41 Million | -169.99 Million | -66.5 Million | -50.49 Million | -30.25 Million |
TITR
BZAMF
0676
NEX
3865
CYB